American Music Tourism Act of 2025

Doctor Knows Best Act of 2025

This joint resolution nullifies the Environmental Protection Agency (EPA) rule titled Greenhouse Gas Emissions Standards for Heavy-Duty Vehicles—Phase 3 and published on April 22, 2024. Heavy-duty vehicles generally include vocational vehicles (such as public utility trucks and school buses) and tractors (such as cabs on tractor-trailer trucks).Among other requirements, the rule phases in standards to reduce greenhouse gas emissions from certain heavy-duty vehicles. The phased-in standards replace previous standards that were established under the EPA's Greenhouse Gas Emissions and Fuel Efficiency Standards for Medium- and Heavy-Duty Engines and Vehicles—Phase 2 rule with more stringent standards.

Reinforcing the Grid Against Extreme Weather Act of 2025

This joint resolution nullifies the Environmental Protection Agency rule titled Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA) (89 Fed. Reg. 102568) and published on December 17, 2024. Among other elements, the rule prohibits the manufacturing, import, processing, and distribution in commerce of trichloroethylene (TCE) for all uses (including consumer uses), and prohibits the industrial and commercial use of TCE.

Honor Our Living Donors Act

Ensuring Accurate and Complete Abortion Data Reporting Act of 2025This bill requires states, as a condition of federal payment under Medicaid for family planning services, to report certain abortion data to the Centers for Disease Control and Prevention (CDC). (Currently, reporting is voluntary.) The CDC must develop standardized questions for states with respect to specified variables (e.g., maternal demographics and methods of abortion).

REDUCE Act Responsive Energy Demand Unlocks Clean Energy Act

Close the Medigap Act of 2025This bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health insurance policies), (2) eliminates certain limitations on Medigap policies for newly eligible Medicare beneficiaries, and (3) modifies other provisions related to Medigap policies. (Guaranteed issue rights require that a policy be offered to any eligible applicant without regard to health status.)

SAFE Grilling Act Strengthening Awareness and Funding Education for Grilling Act

Standing with Moms ActThis bill requires the Department of Health and Human Services (HHS) to disseminate information about pregnancy-related resources, including information about abortion risks and alternatives.Specifically, HHS must create a public website called life.gov that lists such resources that are available through federal, state, and local governments and private entities.Additionally, HHS must create on its existing website a portal that provides a user, based on the user's responses to a series of questions, tailored information about pregnancy resources available in the user's zip code and risks related to abortion. HHS must develop a plan to conduct follow-up outreach to users of the portal (if the user consents to the outreach). States must recommend resources that meet criteria set by HHS for inclusion in the portal. HHS may award grants to states to establish or support a system that aggregates resources to include in the portal.Further, the Health Resources and Services Administration must share information about the new website and portal through the National Maternal Mental Health Hotline.HHS must also ensure that the new website and hotline are available to families who speak languages other than English.The new website, portal, and hotline may not include resources provided by entities that (1) perform, induce, refer for, or counsel in favor of abortions; or (2) financially support such entities.The bill also requires HHS to report on traffic to the new website and portal, gaps in services available to pregnant and postpartum individuals, and related matters.

Spectrum Pipeline Act of 2025

This resolution recognizes domestically produced natural gas as affordable, green, and necessary for the United States to be energy dominant while asserting that the United States should take a broad approach to meet energy needs. It also supports efforts to increase domestic production of natural gas and natural gas infrastructure, identify and remove barriers to the production of natural gas, and expedite the approval of liquefied natural gas export facilities in the United States.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)